Compare AstraZeneca plc (AZN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Xylem, Inc. — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while Xylem, Inc. trades at $121.4 (market cap $28.76B). The key difference: AstraZeneca plc is far larger — about 8.6× Xylem, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | XYL | |
|---|---|---|
Market Cap | $248.14B | $28.76B |
Sector | Health | Industrials |
52-Week High | $209.48 | $152.95 |
52-Week Low | $147.06 | $106.34 |
Enterprise Value | $275.41B | $30.54B |
Dividend Yield | 2.01% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Xylem (XYL) trades at $121.87, up 0.56% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company's fundamentals show robust revenue growth, expanding margins, and healthy cash flow, supported by strategic acquisitions like Cornell Pump and Roper Pump to bolster its industrial water technology presence. Analyst consensus is mixed but leans positive, with a $150.43 price target implying significant upside.
Outlook remains favorable due to secular demand in water infrastructure and AI-driven data centers, though risks include execution on acquisitions and economic sensitivity. The stock offers growth potential from margin expansion and digital water solutions, but investors should monitor integration challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
